Schrödinger Inc. (NASDAQ:SDGR) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET
Company Participants
Ramy Farid - President, Chief Executive Officer
Karen Akinsanya - President, R&D and Therapeutics
Geoff Porges - Chief Financial Officer
Jaren Madden - Senior Vice President, Corporate Affairs and Investor Relations
Conference Call Participants
Matt - Jefferies
Mani Foroohar - Leerink Partners
Steve - Keybanc
Gaspa - Morgan Stanley
Evan Seigerman - BMO Capital Markets
Joe Catanzaro - Piper Sandler
Toff - Craig Hallum
Brendan Smith - TD Cowen
Sean Kim - Bank of America
John - Citi
Operator
Welcome to Schrödinger’s conference call to review our third quarter 2024 financial results. My name is Madison and I will be your Operator for today’s call.
At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing the star and one on your telephone keypad. You may withdraw yourself from the queue by pressing star and two. Please be advised that this call is being recorded at the company’s request.
Now I would like to introduce your host for today’s conference, Jaren Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead.
Jaren Madden
Thank you and good morning everyone. Welcome to today’s call, during which we will provide an update on the company and review our third quarter 2024 financial results.
In addition to our press release announcing our third quarter results, we also issued a press release announcing our new research collaboration and expanded software licensing agreement with Novartis. Both press releases are available on our website at schrodinger.com.
Here with me on our call today are Ramy Farid, Chief Executive Officer, Karen Akinsanya, President of R&D Therapeutics, and Geoff Porges, Chief Financial Officer. Following our prepared remarks, we’ll open the call for Q&A.
During today’s call, management will make statements that are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including without limitation statements related to our outlook for the full year 2024, our plans to accelerate growth of our software business and advance our collaborative and proprietary drug discovery programs, the timing of, initiation of and read-outs from our clinical trials, the clinical potential and properties of our compounds, the anticipated benefits of our collaboration with Novartis, the use of our cash resources, and our future expenses.